High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ¹⁸F-DCFPyL.

ABSTRACT:

Objectives

In patients with prostate cancer (PC) receiving prostate-specific membrane antigen- (PSMA-) targeted radioligand therapy (RLT), higher baseline standardized uptake values (SUVs) are linked to improved outcome. Thus, readers deciding on RLT must have certainty on the repeatability of PSMA uptake metrics. As such, we aimed to evaluate the test-retest repeatability of lesion uptake in a large cohort of patients imaged with ¹⁸F-DCFPyL.

Methods

In this prospective, IRB-approved trial (NCT03793543), 21 patients with history of histologically proven PC underwent two ¹⁸F-DCFPyL PET/CTs within 7 days (mean 3.7, range 1 to 7 days). Lesions in the bone, lymph nodes (LN), and other organs were manually segmented on both scans, and uptake parameters were

SUBMITTER: Werner RA 

PROVIDER: S-EPMC8896803 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature